Key result
Multiple antiplatelet therapy showed no significant difference in platelet function results compared to single antiplatelet therapy after 12 months of dual antiplatelet therapy.
Why the study?
About 9-10% of patients on dual antiplatelet therapy still experience ischemia, prompting examination of platelet function by thromboelastography.
Does multiple antiplatelet therapy compared to single antiplatelet therapy alter platelet function measured by thromboelastography in patients after percutaneous coronary intervention?
Cross-Sectional (n=52)
No
Does multiple antiplatelet therapy compared to single antiplatelet therapy alter platelet function measured by thromboelastography in patients after percutaneous coronary intervention?
There is no significant difference in platelet function measured by thromboelastography between single and dual antiplatelet therapy beyond 12 months post-PCI.
Answers are grounded in this paper and cite their sources.
No support for multiple over single antiplatelet therapy beyond 12 months post-PCI; hypothesis-generating and should not change practice.
Each year, approximately 3 million people with coronary heart disease worldwide undergo percutaneous coronary intervention (PCI). Dual antiplatelet therapy (DAPT) with aspirin and P2Y12 inhibitors became the primary therapy for 6-12 months after PCI. DAPT can be continued > 12 months at a high risk of thrombosis. About 9-10% of patients with dual antiplatelet therapy still experience ischemia. The platelet function examination by thromboelastography (TEG). This research is an analytic observational study using a cross-sectional method. This study was conducted in Saiful Anwar General Hospital. Patients were divided into two groups: (1) on-single antiplatelet therapy; (2) on-dual antiplatelet therapy. The outcome measured result of the platelet function test was divided into standard, low platelet function, and platelet hypercoagulability. An analysis of the differences between single or multiple antiplatelet administration and the platelet function results was performed. There were 52 research subjects, each group of single and multiple antiplatelet therapies as many as 26 people, most of the subjects were male (82.6%) with a mean age of 57. The results of this study showed that there was no significant difference in the results of platelet function examinations between single and multiple antiplatelet therapies after 12 months of dual antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Widito et al. (2020) conducted a cross-sectional in Coronary heart disease after percutaneous coronary intervention (n=52). Multiple antiplatelet therapy vs. Single antiplatelet therapy was evaluated on Platelet function results (standard, low platelet function, and platelet hypercoagulability) by thromboelastography. Multiple antiplatelet therapy showed no significant difference in platelet function results compared to single antiplatelet therapy after 12 months of dual antiplatelet therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: